NASDAQ:PTGX

Protagonist Therapeutics Competitors

$26.22
-0.36 (-1.35 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$25.00
Now: $26.22
$26.91
50-Day Range
$23.57
MA: $27.85
$31.15
52-Week Range
$6.13
Now: $26.22
$32.10
Volume430,580 shs
Average Volume372,407 shs
Market Capitalization$1.15 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.56

Competitors

Protagonist Therapeutics (NASDAQ:PTGX) Vs. AVIR, BHVN, SAGE, HCM, EBS, and ARNA

Should you be buying PTGX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Protagonist Therapeutics, including Atea Pharmaceuticals (AVIR), Biohaven Pharmaceutical (BHVN), Sage Therapeutics (SAGE), Hutchison China MediTech (HCM), Emergent BioSolutions (EBS), and Arena Pharmaceuticals (ARNA).

Protagonist Therapeutics (NASDAQ:PTGX) and Atea Pharmaceuticals (NASDAQ:AVIR) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Insider and Institutional Ownership

97.5% of Protagonist Therapeutics shares are held by institutional investors. 14.2% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Protagonist Therapeutics and Atea Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Protagonist Therapeutics-252.03%-54.00%-35.38%
Atea PharmaceuticalsN/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations for Protagonist Therapeutics and Atea Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Protagonist Therapeutics00703.00
Atea Pharmaceuticals00403.00

Protagonist Therapeutics currently has a consensus target price of $38.00, indicating a potential upside of 44.93%. Atea Pharmaceuticals has a consensus target price of $69.3333, indicating a potential upside of 25.35%. Given Protagonist Therapeutics' higher probable upside, analysts plainly believe Protagonist Therapeutics is more favorable than Atea Pharmaceuticals.

Earnings & Valuation

This table compares Protagonist Therapeutics and Atea Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protagonist Therapeutics$230,000.004,994.11$-77,190,000.00($2.98)-8.80
Atea PharmaceuticalsN/AN/AN/AN/AN/A

Atea Pharmaceuticals has lower revenue, but higher earnings than Protagonist Therapeutics.

Summary

Protagonist Therapeutics beats Atea Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

Protagonist Therapeutics (NASDAQ:PTGX) and Biohaven Pharmaceutical (NYSE:BHVN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Insider and Institutional Ownership

97.5% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 99.4% of Biohaven Pharmaceutical shares are held by institutional investors. 14.2% of Protagonist Therapeutics shares are held by insiders. Comparatively, 19.1% of Biohaven Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Protagonist Therapeutics and Biohaven Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Protagonist Therapeutics-252.03%-54.00%-35.38%
Biohaven PharmaceuticalN/A-1,091.41%-120.85%

Analyst Ratings

This is a breakdown of recent recommendations for Protagonist Therapeutics and Biohaven Pharmaceutical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Protagonist Therapeutics00703.00
Biohaven Pharmaceutical021002.83

Protagonist Therapeutics currently has a consensus target price of $38.00, indicating a potential upside of 44.93%. Biohaven Pharmaceutical has a consensus target price of $96.4545, indicating a potential upside of 36.29%. Given Protagonist Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Protagonist Therapeutics is more favorable than Biohaven Pharmaceutical.

Risk & Volatility

Protagonist Therapeutics has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, Biohaven Pharmaceutical has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500.

Earnings & Valuation

This table compares Protagonist Therapeutics and Biohaven Pharmaceutical's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protagonist Therapeutics$230,000.004,994.11$-77,190,000.00($2.98)-8.80
Biohaven PharmaceuticalN/AN/A$-528,800,000.00($10.91)-6.49

Protagonist Therapeutics has higher revenue and earnings than Biohaven Pharmaceutical. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Biohaven Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Summary

Protagonist Therapeutics beats Biohaven Pharmaceutical on 8 of the 13 factors compared between the two stocks.

Protagonist Therapeutics (NASDAQ:PTGX) and Sage Therapeutics (NASDAQ:SAGE) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Insider and Institutional Ownership

97.5% of Protagonist Therapeutics shares are held by institutional investors. 14.2% of Protagonist Therapeutics shares are held by insiders. Comparatively, 4.8% of Sage Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Protagonist Therapeutics and Sage Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Protagonist Therapeutics-252.03%-54.00%-35.38%
Sage Therapeutics-7,706.84%-63.81%-56.64%

Analyst Ratings

This is a breakdown of recent recommendations for Protagonist Therapeutics and Sage Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Protagonist Therapeutics00703.00
Sage Therapeutics08802.50

Protagonist Therapeutics currently has a consensus target price of $38.00, indicating a potential upside of 44.93%. Sage Therapeutics has a consensus target price of $87.0625, indicating a potential upside of 16.58%. Given Protagonist Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Protagonist Therapeutics is more favorable than Sage Therapeutics.

Risk & Volatility

Protagonist Therapeutics has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, Sage Therapeutics has a beta of 2.23, suggesting that its share price is 123% more volatile than the S&P 500.

Earnings & Valuation

This table compares Protagonist Therapeutics and Sage Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protagonist Therapeutics$230,000.004,994.11$-77,190,000.00($2.98)-8.80
Sage Therapeutics$6.87 million634.64$-680,240,000.00($13.38)-5.58

Protagonist Therapeutics has higher earnings, but lower revenue than Sage Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Protagonist Therapeutics beats Sage Therapeutics on 10 of the 14 factors compared between the two stocks.

Protagonist Therapeutics (NASDAQ:PTGX) and Hutchison China MediTech (NASDAQ:HCM) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Insider and Institutional Ownership

97.5% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 33.5% of Hutchison China MediTech shares are held by institutional investors. 14.2% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Protagonist Therapeutics and Hutchison China MediTech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Protagonist Therapeutics-252.03%-54.00%-35.38%
Hutchison China MediTechN/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations for Protagonist Therapeutics and Hutchison China MediTech, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Protagonist Therapeutics00703.00
Hutchison China MediTech00203.00

Protagonist Therapeutics currently has a consensus target price of $38.00, indicating a potential upside of 44.93%. Hutchison China MediTech has a consensus target price of $40.00, indicating a potential upside of 36.52%. Given Protagonist Therapeutics' higher probable upside, analysts plainly believe Protagonist Therapeutics is more favorable than Hutchison China MediTech.

Risk & Volatility

Protagonist Therapeutics has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, Hutchison China MediTech has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.

Earnings & Valuation

This table compares Protagonist Therapeutics and Hutchison China MediTech's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protagonist Therapeutics$230,000.004,994.11$-77,190,000.00($2.98)-8.80
Hutchison China MediTech$204.89 million20.81$-106,020,000.00($0.80)-36.63

Protagonist Therapeutics has higher earnings, but lower revenue than Hutchison China MediTech. Hutchison China MediTech is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Protagonist Therapeutics beats Hutchison China MediTech on 8 of the 13 factors compared between the two stocks.

Protagonist Therapeutics (NASDAQ:PTGX) and Emergent BioSolutions (NYSE:EBS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for Protagonist Therapeutics and Emergent BioSolutions, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Protagonist Therapeutics00703.00
Emergent BioSolutions02502.71

Protagonist Therapeutics currently has a consensus target price of $38.00, indicating a potential upside of 44.93%. Emergent BioSolutions has a consensus target price of $109.8333, indicating a potential upside of 44.78%. Given Protagonist Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Protagonist Therapeutics is more favorable than Emergent BioSolutions.

Earnings & Valuation

This table compares Protagonist Therapeutics and Emergent BioSolutions' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protagonist Therapeutics$230,000.004,994.11$-77,190,000.00($2.98)-8.80
Emergent BioSolutions$1.11 billion3.66$54.50 million$2.9126.07

Emergent BioSolutions has higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Protagonist Therapeutics and Emergent BioSolutions' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Protagonist Therapeutics-252.03%-54.00%-35.38%
Emergent BioSolutions12.50%26.68%12.70%

Insider and Institutional Ownership

97.5% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 80.2% of Emergent BioSolutions shares are held by institutional investors. 14.2% of Protagonist Therapeutics shares are held by insiders. Comparatively, 14.1% of Emergent BioSolutions shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Protagonist Therapeutics has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, Emergent BioSolutions has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500.

Arena Pharmaceuticals (NASDAQ:ARNA) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for Arena Pharmaceuticals and Protagonist Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arena Pharmaceuticals001503.00
Protagonist Therapeutics00703.00

Arena Pharmaceuticals currently has a consensus target price of $91.80, suggesting a potential upside of 41.75%. Protagonist Therapeutics has a consensus target price of $38.00, suggesting a potential upside of 44.93%. Given Protagonist Therapeutics' higher probable upside, analysts clearly believe Protagonist Therapeutics is more favorable than Arena Pharmaceuticals.

Earnings and Valuation

This table compares Arena Pharmaceuticals and Protagonist Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arena Pharmaceuticals$806.43 million4.85$397.55 million$7.698.42
Protagonist Therapeutics$230,000.004,994.11$-77,190,000.00($2.98)-8.80

Arena Pharmaceuticals has higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Arena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Arena Pharmaceuticals and Protagonist Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arena PharmaceuticalsN/A-33.17%-30.41%
Protagonist Therapeutics-252.03%-54.00%-35.38%

Insider & Institutional Ownership

89.7% of Arena Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.5% of Protagonist Therapeutics shares are owned by institutional investors. 3.1% of Arena Pharmaceuticals shares are owned by insiders. Comparatively, 14.2% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Arena Pharmaceuticals has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500.

Summary

Arena Pharmaceuticals beats Protagonist Therapeutics on 8 of the 13 factors compared between the two stocks.


Protagonist Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$55.31-2.2%$4.58 billionN/A0.00
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$70.77-1.9%$4.39 billionN/A-5.77Analyst Revision
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$74.68-2.6%$4.36 billion$6.87 million-7.22Analyst Report
Analyst Revision
News Coverage
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.30-0.2%$4.26 billion$204.89 million-36.63
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$75.86-2.0%$4.04 billion$1.11 billion24.39
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$64.76-2.4%$3.91 billion$806.43 million-9.17Unusual Options Activity
LEGN
Legend Biotech
1.2$27.81-2.3%$3.67 billion$64.39 million0.00
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$74.94-5.4%$3.67 billionN/A-21.35News Coverage
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$52.24-1.0%$3.64 billion$117.91 million-10.60
I-Mab logo
IMAB
I-Mab
1.4$47.86-7.9%$3.44 billion$4.31 million-1.66
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.68-0.3%$3.41 billion$114.62 million-7.53Analyst Revision
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$41.59-0.1%$3.34 billionN/A-5.61
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.13-1.0%$3.31 billion$306.98 million-6.74
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.43-0.2%$3.27 billion$339.08 million-11.88
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.31-6.7%$3.23 billion$36.13 million-69.12Unusual Options Activity
News Coverage
Insmed logo
INSM
Insmed
1.2$30.82-2.9%$3.18 billion$136.47 million-11.85
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$85.87-3.0%$3.11 billion$26.52 million-7.57
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$112.62-3.8%$3.04 billionN/A-56.03
Alkermes logo
ALKS
Alkermes
1.4$18.78-1.3%$2.99 billion$1.17 billion-40.83Unusual Options Activity
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$67.95-0.4%$2.98 billion$421.03 million23.93Analyst Report
Analyst Revision
Arvinas logo
ARVN
Arvinas
1.5$60.45-5.0%$2.95 billion$42.98 million-23.61
Organogenesis logo
ORGO
Organogenesis
1.0$22.98-0.6%$2.94 billion$260.98 million-383.00Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$22.17-0.9%$2.92 billion$80.43 million105.58
Viela Bio logo
VIE
Viela Bio
0.8$53.01-0.0%$2.91 billion$50 million-7.55
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.59-0.3%$2.78 billion$644.77 million-10.36
OPKO Health logo
OPK
OPKO Health
1.9$4.06-3.0%$2.72 billion$901.90 million-22.55
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.43-1.1%$2.63 billion$306.49 million25.20
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.71-0.1%$2.57 billion$60,000.00-9.85News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$44.05-0.5%$2.54 billion$25 million-8.81
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$40.97-3.8%$2.53 billionN/A-22.51
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$39.97-2.0%$2.48 billion$2.11 million-8.65
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.29-1.1%$2.46 billion$182.24 million-8.08
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$144.90-5.9%$2.41 billion$120.28 million-146.36
Cryoport logo
CYRX
Cryoport
1.9$51.64-1.3%$2.36 billion$33.94 million-89.03Insider Selling
ALX Oncology logo
ALXO
ALX Oncology
1.9$57.95-10.0%$2.33 billionN/A0.00
Amarin logo
AMRN
Amarin
1.6$5.84-1.5%$2.30 billion$429.76 million-116.78
Xencor logo
XNCR
Xencor
1.2$39.59-2.2%$2.29 billion$156.70 million-28.28News Coverage
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$44.30-1.2%$2.21 billion$963.01 million13.76News Coverage
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$30.49-2.7%$2.16 billion$15 million-15.96
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.18-0.3%$2.00 billion$23.90 million-16.26Analyst Revision
News Coverage
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.91-0.8%$1.99 billion$410,000.00-6.07
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$51.89-2.1%$1.94 billionN/A-19.29
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$62.10-10.3%$1.91 billionN/A-26.43Gap Down
Kura Oncology logo
KURA
Kura Oncology
1.6$28.62-0.2%$1.89 billionN/A-17.56
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$24.53-3.7%$1.88 billion$103.54 million-18.44
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02-0.0%$1.88 billionN/A-10.57
MORF
Morphic
1.1$57.73-2.8%$1.87 billion$16.98 million-37.01Insider Selling
News Coverage
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.16-2.1%$1.85 billion$34.51 million-17.23
FibroGen logo
FGEN
FibroGen
1.8$19.89-6.6%$1.82 billion$256.58 million-7.62Analyst Revision
MacroGenics logo
MGNX
MacroGenics
1.4$30.07-3.6%$1.80 billion$64.19 million-9.61
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.